|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hacker NF, Eifel PJ and Van der Velden J:
Cancer of the vagina. Int J Gynaecol Obstet. 131 Suppl 2:S84–S87.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Creasman WT, Phillps JL and Menck HR: The
national cancer data base report on cancer of the vagina. Cancer.
83:1033–1040. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beller U, Benedet JL, Creasman WT, Nqan
HY, Quinn MA, Maisonneuve P, Pecorelli S, Odicino F and Heintz AP:
Carcinoma of the vagina. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95 Suppl
1:S29–S42. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hiniker SM, Roux A, Murphy JD, Harris JP,
Tran PT, Kapp DS and Kidd EA: Primary squamous cell carcinoma of
the vagina: Prognostic factors, treatment patterns, and outcomes.
Gynecol Oncol. 131:380–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Platta CS, Anderson B, Geye H, Das R,
Straub M and Bradley K: Adjuvant and definitive radiation therapy
for primary carcinoma of the vagina using brachytherapy and
external beam radiation therapy. J contemp Brachytherapy. 5:76–82.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tjalma WA, Monaghan JM, de Barros Lopes A,
Naik R, Nordin AJ and Weyler JJ: The role of surgery in invasive
squamous carcinoma of the vagina. Gynecol Oncol. 81:360–365. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sinha B, Stehman F, Schilder J, Clark L
and Cardense H: Indiana University experience in the management of
vaginal cancer. Int J Gynecol Cancer. 19:686–693. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Umesaki N, Kawamura N, Tsujimura A,
Ichimura T, Tanaka T and Oqita S: Stage II vaginal cancer
responding to chemotherapy with irinotecan and cisplatin: A case
report. Oncol Rep. 6:123–125. 1999.PubMed/NCBI
|
|
10
|
Mabuchi Y, Yahata T, Kobayashi A, Tanizaki
Y, Minami S and Ino K: Vaginal carcinoma in a young woman who
underwent fertility-sparing treatment involving chemotherapy and
conservative surgery. J Obstet Gynaecol Res. 41:989–992. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Panici P Benedetti, Bellati F, Plotti F,
Di Donato V, Antonilli M, Perniola G, Manci N, Muzii L and Angioli
R: Neoadjuvant chemotherapy followed by radical surgery in patients
affected by vaginal carcinoma. Gynecol Oncol. 111:307–311. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv L, Sun Y, Liu H, Lou J and Peng Z:
Neoadjuvant chemotherapy followed by radical surgery and
reconstruction of the vagina in a patient with stage II primary
vaginal squamous carcinoma. J Obstet Gynaecol Res. 36:1245–1248.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsubamoto H, Kanazawa R, Inoue K, Ito Y,
Komori S, Maeda H and Hirota S: Fertility-sparing management for
bulky cervical cancer using neoadjuvant transuterine arterial
chemotherapy followed by vaginal trachelectomy. Int J Gynecol
Cancer. 22:1057–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pareja R, Rendón GJ, Vasquez M, Echeverri
L, Sanz-Lomana CM and Ramirez PT: Immediate radical trachelectomy
versus neoadjuvant chemotherapy followed by conservative surgery
for patients with stage IB1 cervical cancer with tumors 2 cm or
larger: A literature review and analysis of oncological and
obstetrical outcomes. Gynecol Oncol. 137:574–580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Robova H, Halaska MJ, Pluta M, Skapa P,
Matecha J, Lisy J and Rob L: Oncological and pregnancy outcomes
after high-dose density neoadjuvant chemotherapy and
fertility-sparing surgery in cervical cancer. Gynecol Oncol.
135:213–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hellman K, Silfverswärd C, Nilsson B,
Hellström AC, Frankendal B and Pettersson F: Primary carcinoma of
the vagina: Factors influencing the age at diagnosis. The
rediumhemmet series 1956–96. Int J Gynecol cancer. 14:491–501.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Daling JR, Madeleine MM, Schwartz SM,
Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall
JK and Tamimi H: A population based study of squamous cell vaginal
cancer: HPV and cofactors. Gynecol Oncol. 84:263–270. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Larsson GL, Helenius G, Andersson S, Sorbe
B and Karisson MG: Prognostic impact of human papilloma virus (HPV)
genotyping and HPV-16 subtyping in vaginal carcinoma. Gynecol
Oncol. 129:406–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blecharz P, Reinfuss M, Jakubowicz J,
Piotr S, Wysocki W, Karolewski K and Urbański K: Prognostic factors
in patients with primary invasive vaginal carcinoma. Ginekol Pol.
83:904–909. 2012.PubMed/NCBI
|
|
20
|
Ramesh M, Ahlawat P and Srinivas NR:
Irinotecan and its active metabolite, SN-38: Review of
bioanalytieal methods and recent update from clinical pharmacology
perspectives. Biomed Chromatogr. 24:104–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaguchi S, Nishimura R, Yaegashi N,
Kiguchi K, Sugiyama T, Kita T, Kubushiro K, Kokawa K, Hiura M,
Mizutani K, et al: Phase II study of neoadjuvant chemotherapy with
irinotecan hydrochloride and nedaplatin followed by radical
hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell
carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
Oncol Rep. 28:487–493. 2012.PubMed/NCBI
|
